Dublin, Ireland. 14 December, 2018. Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), a 100% subsidiary of Otsuka Holdings Co., Ltd., and Veryan Medical Ltd. (“Veryan”) have announced the completion of the acquisition of Veryan by Otsuka Medical Devices through its UK subsidiary Otsuka Medical Devices UK Ltd. Veryan’s BioMimics 3D peripheral vascular stent received […]
Otsuka Medical Devices Acquires Veryan. Read More »
Galway, Ireland. 13 November 2018. Seroba’s portfolio company, Atlantic Therapeutics, a global manufacturer of innovative, garment-based pelvic floor muscle strengthening and nerve stimulation products, has announced that the U.S. Food and Drug Administration (FDA) has granted a DeNovo clearance for its INNOVO® therapy device, an externally-worn electrical muscle stimulator for the treatment of stress urinary
Atlantic Therapeutics Secures FDA Approval. Read More »
Horsham, UK. 05 October 2018. Seroba Investee, Veryan Medical Ltd, today announced that the Company has received Premarket Approval (PMA) for the BioMimics 3D Vascular Stent System from the U.S. Food & Drug Administration (FDA). The device is approved for the treatment of symptomatic de novo or restenotic lesions in the native superficial femoral artery
Veryan Receives PreMarket Approval. Read More »
Alcester, UK. 1 October 2018. Quanta Dialysis Technologies Ltd (“Quanta”), a medical device company pioneering innovative haemodialysis products for dialysis patients, is pleased to announce that it has won the “Industrial Product Design of the Year” award at the Plastics Industry Awards 2018. John E. Milad, Chief Executive Officer of Quanta, said: “I am delighted
Quanta Wins Industrial Product Design 2018. Read More »
Ireland and USA. 14 Sept 2018. Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure, today announced the close of a Series D financing round totaling $45 million. The round was led by LSP, investing from its LSP Health Economics Fund 2, and included Aperture Venture Partners, BioVentures Investors,
Endotronix Raises $45M Series D Financing. Read More »
Dublin, Ireland. 7 Sept 2018. TG plc (LSE:BTG) (BTG) and Seroba’s portfolio company, Novate, today announced the signing of a definitive agreement in which BTG has acquired Novate for a $20m upfront payment with additional potential milestones of up to $130m. Novate which is based in Galway has developed a novel blood filter device (“Sentry”)
Novate Acquired By BTG for Up To $150m. Read More »
California, USA. 17 July, 2018. Labcyte Inc., today announced an agreement with the Center for Excellence in Engineering Biology (CEEB), an independent nonprofit that is managing initial planning and coordination of efforts for the Genome Project-write (GP-write). As part of the agreement, Labcyte will provide preferred pricing and in-kind support to researchers at qualified laboratories
Labcyte Partners with GP-write in Large-Scale Genomic Testing. Read More »
Milpitas, California. 28 June 2018. Results from the DETOUR I Trial evaluating the PQ Bypass DETOUR System for percutaneous bypass showed promising 12-month durability for patients with extremely long blockages in the superficial femoral artery (SFA). The data were presented as a late-breaking clinical trial session last week at the Society for Vascular Surgery (SVS)
PQ Bypass Reports Positive 12-Month Results. Read More »
Alcester, UK. 25 April 2018. Seroba’s investee company Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical device company providing innovative haemodialysis solutions, has announced that it has successfully completed a clinical pilot to treat patients in France. Building off its successful UK pilot, this is the first time Quanta’s personal haemodialysis system, SC+
Quanta Successfully Completes Pilot Treatments in France. Read More »
Oss, The Netherlands & Dublin, Ireland. 16 March 2018. H. Lundbeck A/S (Lundbeck) and Seroba’s Investee Company, Prexton Therapeutics BV (Prexton), today announced the signing of a definitive agreement in which Lundbeck will acquire Prexton. Under the terms of the agreement, Lundbeck will pay EUR 100 million upfront plus EUR 805 million in development and
Prexton Acquired by Lundbeck for up to €905m. Read More »